Against the backdrop of the growing epidemic of obesity in the United States, scientists from the Florida campus of The Scripps Research Institute have made an important new discovery regarding a specific gene that plays an important role in keeping a steady balance between our food intake and energy expenditure. The study may help scientists better understand the keys to fighting obesity and related disorders such as diabetes. The study, which was published in the November 25, 2011 print edition of The Journal of Biological Chemistry, focused on the melanocortin-3 receptor (MC3R), which normally responds to signals of nutrient intake. "What we discovered was quite a surprise, " said Scripps Research Associate Professor Andrew Butler, who led the study. "We thought that the actions of the receptor expressed in the brain would be critical for metabolic homeostasis.
Boehringer Ingelheim and Eli Lilly and Company announced their results of a 24-week open label arm of a phase III study for linagliptin in initial combination with metformin at the International Diabetes Federation (IDF) World Diabetes Congress in Dubai. The results showed important reductions in blood glucose for adults with Type 2 Diabetes (T2D). After 24 weeks the study demonstrated that poorly controlled patients who received the initial combination therapy of linagliptin with metformin achieved an average HbA1c reduction of -3.7%. According to the researchers the treatment was well tolerated. 9% of patients suffered drug-related adverse events (AEs) and just 1.5% developed hypoglycemia. Professor Klaus Dugi, Corporate Senior Vice President Medicine at Boehringer Ingelheim said: "Many patients with high HbA1c levels require more than metformin alone to reach their blood glucose targets.
An inexpensive drug that treats Type-2 diabetes has been shown to prevent a number of natural and man-made chemicals from stimulating the growth of breast cancer cells, according to a newly published study by a Michigan State University researcher. The research, led by pediatrics professor James Trosko and colleagues from South Korea's Seoul National University, provides biological evidence for previously reported epidemiological surveys that long-term use of the drug metformin for Type-2 diabetes reduces the risk of diabetes-associated cancers, such as breast cancers. The research appears in the current edition of PLoS One. "People with Type-2 diabetes are known to be at high risk for several diabetes-associated cancers, such as breast, liver and pancreatic cancers, " said Trosko, a professor in the College of Human Medicine's Department of Pediatrics and Human Development.
An inexpensive, culturally sensitive diabetes prevention program created by researchers at the University of Massachusetts Medical School reduced pre-diabetes indicators in a Latino population at risk for developing diabetes. Results of this three-year study, which were published online in the American Journal of Public Health, are significant because they replicate results of earlier studies that were similar but carried out in more educated and higher-income populations, and much more expensive to conduct. The model for the Lawrence intervention could provide an affordable approach for similar low-income populations. The Lawrence Latino Diabetes Prevention Project, a $2.6 million clinical trial funded by the National Institute of Diabetes and Digestive and Kidney Diseases at the National Institutes of Health (NIH) in 2004, brought together an array of community groups in Lawrence to introduce weight control, nutrition and exercise programs to Lawrence Latinos who were at risk for developing type 2 diabetes.
Takeda Submits New Drug Application In The U.S. For Investigational Type 2 Diabetes Therapy, Fixed-Dose Combination Alogliptin Metformin
Takeda Pharmaceutical Company Limited (Takeda) announced that its wholly-owned subsidiary Takeda Global Research & Development Center, Inc., U.S., submitted a New Drug Application (NDA) to the United States (U.S.) Food and Drug Administration (FDA) for the fixed-dose combination therapy alogliptin/metformin, which combines alogliptin with metformin in a single tablet. The FDA is expected to review the NDA submission within the next ten months, the standard review period for a new application. "This NDA submission further extends Takeda's commitment to offering patients with type 2 diabetes a range of therapeutic options to help them manage their condition, " noted Thomas Strack, M.D., vice president, clinical science, Takeda Global Research & Development Center, Inc., U.S. "The worldwide incidence of type 2 diabetes continues to expand at a rapid rate and we continue our research into additional medications to treat these patients.